TAO Synergies Reports Revenue Surge to $88,626 and Reduced Losses in Q2 2026

TAO Synergies Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $88,626 from staking its TAO tokens, a substantial increase from $3,962 in the same period last year. For the first half of 2026, total revenues reached $477,400, compared to just $3,962 in the first half of 2025. This growth is attributed to a more aggressive strategy in purchasing and staking TAO tokens throughout the current fiscal year.

Operating expenses for the second quarter of 2026 totaled $1,657,862, down 45.5% from $3,039,795 in the prior year. The decrease was primarily driven by a significant reduction in research and development expenses, which fell by 78.6% to $31,855, as the company concluded its Cleveland Clinic trial for Alzheimer's disease and discontinued its multiple sclerosis clinical trial. General and administrative expenses also decreased by 25.8% to $1,626,007, reflecting a reduction in legal and consulting fees associated with the company's strategic shift towards cryptocurrency.

The company reported a net loss of $9,298,966 for the second quarter, a 46.9% improvement compared to a loss of $17,516,078 in the same quarter of 2025. This reduction in losses was largely due to lower operating expenses and a decrease in other expenses, which fell from $14,480,245 to $7,729,730. The latter included unrealized losses on digital assets and changes in the fair value of warrant and derivative liabilities.

TAO Synergies has also made strategic moves to enhance its cryptocurrency treasury strategy, focusing on the TAO token, the native cryptocurrency of the Bittensor network. As of June 30, 2026, approximately 87.7% of the company's treasury holdings were invested in TAO. The company has not yet monetized any of its TAO holdings but continues to stake the majority of its tokens to generate revenue. The company’s total assets decreased to $21.1 million from $25.8 million at the end of 2025, with cash and cash equivalents dropping to $2.4 million.

Looking ahead, TAO Synergies anticipates that its current cash and digital asset holdings will be sufficient to support its operational needs for at least the next 12 months. However, the company acknowledges the need for additional capital to continue its development programs, particularly for its Bryostatin-1 therapeutic candidate. The company is exploring various financing options, including potential equity or debt offerings, but warns that such funding may not be available on favorable terms.